One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease
NCT ID: NCT04148820
Last Updated: 2019-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2019-11-01
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Uncertainty about the optimal timing and clinical implications of administration of cardiovascular drugs still persists.
The investigators will perform a pilot randomized trial to evaluate the efficacy and safety of a one daily administration of multiple drugs vs. twice daily administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
NCT02144831
Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study
NCT01534026
Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI
NCT02640794
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
NCT01360047
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes
NCT01322711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These drugs are usually given at different timetables. Recent investigations, however, have demonstrated that adherence to medical treatment is significantly greater if a one daily strategy is adopted.
Uncertainty about the optimal timing and clinical implications of administration of cardiovascular drugs still persists.
The investigators will perform a pilot randomized trial to evaluate the efficacy and safety of a one daily administration of multiple drugs vs. twice daily administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Once daily drug administration
Patients will be given cardiovascular drugs once daily
Aspirin, Atorvastatin, Perindopril
Cardiovascular drugs will be administered all together every day at the same time
Twice daily drug administration
Patients will be given cardiovascular drugs twice daily
Aspirin, Atorvastatin, Perindopril
Cardiovascular drugs will be administered all together every day at the same time
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin, Atorvastatin, Perindopril
Cardiovascular drugs will be administered all together every day at the same time
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Roma La Sapienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francesco Pelliccia
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Marazzi
Role: STUDY_DIRECTOR
San Raffaele Pisana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Raffaele Pisana
Rome, , Italy
Sapienza University
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/D/789
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.